Differences in Biomarker Expression in GBM Patients with Early Progression After Surgery | Caris Life Sciences
Home / Research / Publications / Differences in Biomarker Expression in GBM Patients with Early Progression After Surgery

Publications

Differences in Biomarker Expression in GBM Patients with Early Progression After Surgery

Purpose

  • Glioblastoma Multiforme (GBM) is locally aggressive
  • GBM is the most common primary brain tumor in adults
  • Surgery followed by temozolomide and radiotherapy are the standard of care
  • Attempts have been made to increase radiation dose, pursue more aggressive chemotherapy, or add targeted therapy
  • Biomarker expression may help individualize treatment decisions

Download Publication
Learn More
Name(Required)